Search for: "Teva Pharmaceuticals"
Results 541 - 560
of 1,424
Sort by Relevance
|
Sort by Date
1 Jun 2015, 5:53 am
Arthrex premised its motion on the argument that the judgment should be reopened in light of the Supreme Court's recent holding in Teva Pharmaceuticals USA, Inc. v. [read post]
26 May 2015, 7:06 am
The court denied defendant's motion to reopen the judgment and rejected its argument that Teva Pharmaceuticals USA, Inc. v. [read post]
25 May 2015, 4:15 am
.* Colourless Copaxone in the clear: Teva's synthesis patents held to be (mostly) validThe never-ending litigation between Synthon and Teva over Copaxone (glatiramer acetate) has already given us interesting and striking decisions from the Patents Court [also here], the Court of Appeal in England, and also the US Supreme Court. [read post]
22 May 2015, 10:38 am
Shortly afterwards, the injunction on Krka was lifted.The declaration of non-infringement awarded to Ranbaxy opened the door to the marketing of generic esomeprazole products by a series of other companies, including Arrow, Mylan and Teva. [read post]
21 May 2015, 10:39 am
The parties have been back in court to fight over other patents, resulting in the decision Synthon B.V. v Teva Pharmaceutical Industries Ltd [2015] EWHC 1395 (Pat), which came out this morning.The patents concerned are EP (UK) 2 177 528 and EP (UK) 2 361 924, both divisionals of EP (UK) 1 799 703, which was revoked by the EPO in opposition proceedings pursuant to Teva's withdrawal of it after a negative preliminary opinion. [read post]
18 May 2015, 11:01 am
******************PREVIOUSLY, ON NEVER TOO LATENever too late 45 [week ending on Sunday 10 May] – INTA 2015 and the Kat | IP and Competition Law | Sky v Skype | CJEU v Spain | Digital Single Market Strategy | IPCom v HTC | European Qualifying Examination appealed | UPC fees | CJEU and 3-D marks | EPO Oral Proceedings.Never too late 44 [week ending on Sunday 3 May] – Forgotten principles and histories, and the role of complexity in patent law… [read post]
14 May 2015, 4:00 am
Mylan Pharmaceuticals ULC, 2015 FC 17[7] [tadalafil Notice of Compliance case (“NOC”)], Justice de Montigny accepted that Eli Lilly’s patent for the new use of a drug to treat erectile dysfunction (“ED”) only promised ED treatment. [read post]
13 May 2015, 7:41 am
The serendipitous discovery became the drug with the biggest sales by an Israeli pharmaceutical company. [read post]
11 May 2015, 3:05 pm
******************PREVIOUSLY, ON NEVER TOO LATENever too late 44 [week ending on Sunday 3 May] – Forgotten principles and histories, and the role of complexity in patent law | King's College copyright distance learning Course | Spain, Berne, and the non-discrimination principle | Novartis v Focus, Actavis, Teva | SUEPO keeps demonstrating | Popcorn's blocking injunction | Unprecedented pre-action disclosure application in Arnoldian Big Bus v… [read post]
3 May 2015, 10:33 pm
With this note, he provides further food for thought on patent law’s complexity, from Bilski to Teva v Leo Pharma, to the relation between patent law and economics. [read post]
27 Apr 2015, 1:28 pm
Supreme Court on Monday rejected Teva Pharmaceuticals USA Inc.'s request to review a Pennsylvania appellate ruling that federal law did not preempt the product liability claims of thousands of generic Reglan users. [read post]
27 Apr 2015, 10:56 am
The only reference to starting dose was as follows:The TTS of the invention allows, e.g., the manufacture of once a day pharmaceutical forms for patients who have to take more than one dose of an active agent per day, e.g., at specific times, so that their treatment is simplified. [read post]
26 Apr 2015, 6:14 pm
As an example if one considers how inventive step was assessed in Teva UK Limited & Teva Pharmaceuticals Limited v Leo Pharma A/S & Leo Laboratories Limited [2014] EWHC 3096 (Pat) (see Katpost here) one sees that for a pharmaceutical formulation the following criteria may be relevant:* obvious to try * reasonable expectation of success * prejudice * inventive selection * the Technograph test (Technograph v Mills & Rockley [1972] RPC… [read post]
24 Apr 2015, 3:42 am
Jonas Anderson and Peter Menell discuss the Court’s recent decision in Teva Pharmaceuticals v. [read post]
17 Apr 2015, 12:05 pm
Cir.2015).We then review that construction according to the standard set forth in Teva Pharmaceuticals U.S.A., Inc. v. [read post]
1 Apr 2015, 5:00 am
This year the pharmaceutical world has already seen some incredible mergers and acquisitions. [read post]
1 Apr 2015, 5:00 am
This year the pharmaceutical world has already seen some incredible mergers and acquisitions. [read post]
26 Mar 2015, 9:59 pm
At issue were two Cadence Pharmaceuticals patents: U.S. [read post]
19 Mar 2015, 12:41 pm
Teva sells a copy of Neupogen, called Granix, but it was approved via the process for a novel drug, not as a biosimilar. [read post]
15 Mar 2015, 6:18 pm
The proposed bill reflects a basic misunderstanding of the pharmaceutical marketplace, and attempts to impose brand pharmaceutical provisions on generic drugs. [read post]
